10/04/2019 13:30:00

New Research: Key Drivers of Growth for Newmont Mining, Johnson & Johnson, Portola Pharmaceuticals, MedEquities Realty Trust, Comtech Telecommunications, and Odonate Therapeutics — Factors of Influence, Major Initiatives and Sustained Production

NEW YORK, April 10, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Newmont Mining Corporation (NYSE:NEM), Johnson & Johnson (NYSE:JNJ), Portola Pharmaceuticals, Inc. (NASDAQ:PTLA), MedEquities Realty Trust Inc. (NYSE:MRT), Comtech Telecommunications Corp. (NASDAQ:CMTL), and Odonate Therapeutics, Inc. (NASDAQ:ODT), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

NEM DOWNLOAD: https://Capital-Review.com/register/?so=NEM

JNJ DOWNLOAD: https://Capital-Review.com/register/?so=JNJ

PTLA DOWNLOAD: https://Capital-Review.com/register/?so=PTLA

MRT DOWNLOAD: https://Capital-Review.com/register/?so=MRT

CMTL DOWNLOAD: https://Capital-Review.com/register/?so=CMTL

ODT DOWNLOAD: https://Capital-Review.com/register/?so=ODT

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Capital Review, available for free download at the links above, examine Newmont Mining Corporation (NYSE:NEM), Johnson & Johnson (NYSE:JNJ), Portola Pharmaceuticals, Inc. (NASDAQ:PTLA), MedEquities Realty Trust Inc. (NYSE:MRT), Comtech Telecommunications Corp. (NASDAQ:CMTL), and Odonate Therapeutics, Inc. (NASDAQ:ODT) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice:

the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

NEWMONT MINING CORPORATION (NEM) REPORT OVERVIEW

Newmont Mining's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Newmont Mining reported revenue of $2,048.00MM vs $1,935.00MM (up 5.84%) and analysts estimated basic earnings per share $0.00 vs -$1.01. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Newmont Mining reported revenue of $7,253.00MM vs $7,379.00MM (down 1.71%) and analysts estimated basic earnings per share $0.64 vs -$0.21. Analysts expect earnings to be released on April 25th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.35. The estimated EPS forecast for the next fiscal year is $1.27 and is expected to report on February 20th, 2020.

To read the full Newmont Mining Corporation (NEM) report, download it here: https://Capital-Review.com/register/?so=NEM

-----------------------------------------

JOHNSON & JOHNSON (JNJ) REPORT OVERVIEW

Johnson & Johnson's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Johnson & Johnson reported revenue of $20,394.00MM vs $20,195.00MM (up 0.99%) and analysts estimated basic earnings per share $1.13 vs -$3.97. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Johnson & Johnson reported revenue of $81,581.00MM vs $76,450.00MM (up 6.71%) and analysts estimated basic earnings per share $5.70 vs $0.48 (up 1,087.50%). Analysts expect earnings to be released on April 16th, 2019. The report will be for the fiscal period ending March 31st, 2019. Based on 7 analysts' forecasts, the consensus EPS forecast for the quarter is $1.95. Reported EPS for the same quarter last year was $2.06. The estimated EPS forecast for the next fiscal year is $9.21 and is expected to report on January 28th, 2020.

To read the full Johnson & Johnson (JNJ) report, download it here: https://Capital-Review.com/register/?so=JNJ

-----------------------------------------

PORTOLA PHARMACEUTICALS, INC. (PTLA) REPORT OVERVIEW

Portola Pharmaceuticals' Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, Portola Pharmaceuticals reported revenue of $15.30MM vs $9.80MM (up 56.05%) and analysts estimated basic earnings per share -$1.34 vs -$1.44. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Portola Pharmaceuticals reported revenue of $40.13MM vs $22.55MM (up 77.99%) and analysts estimated basic earnings per share -$5.31 vs -$4.81. Analysts expect earnings to be released on May 8th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$1.28. The estimated EPS forecast for the next fiscal year is -$2.42 and is expected to report on March 6th, 2020.

To read the full Portola Pharmaceuticals, Inc. (PTLA) report, download it here: https://Capital-Review.com/register/?so=PTLA

-----------------------------------------

MEDEQUITIES REALTY TRUST INC. (MRT) REPORT OVERVIEW

MedEquities Realty Trust's Recent Financial Performance

For the three months ended December 31st, 2018 vs December 31st, 2017, MedEquities Realty Trust reported revenue of $13.31MM vs $16.23MM (down 18.03%) and basic earnings per share -$0.02 vs $0.18. For the twelve months ended December 31st, 2018 vs December 31st, 2017, MedEquities Realty Trust reported revenue of $57.26MM vs $61.11MM (down 6.29%) and analysts estimated basic earnings per share $0.17 vs $0.64 (down 73.44%). Analysts expect earnings to be released on May 9th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.30.

To read the full MedEquities Realty Trust Inc. (MRT) report, download it here: https://Capital-Review.com/register/?so=MRT

-----------------------------------------

COMTECH TELECOMMUNICATIONS CORP. (CMTL) REPORT OVERVIEW

Comtech Telecommunications' Recent Financial Performance

For the three months ended January 31st, 2019 vs January 31st, 2018, Comtech Telecommunications reported revenue of $164.13MM vs $133.73MM (up 22.73%) and analysts estimated basic earnings per share $0.33 vs $0.66 (down 50.00%). For the twelve months ended July 31st, 2018 vs July 31st, 2017, Comtech Telecommunications reported revenue of $570.59MM vs $550.37MM (up 3.67%) and analysts estimated basic earnings per share $1.25 vs $0.68 (up 83.82%). Analysts expect earnings to be released on June 5th, 2019. The report will be for the fiscal period ending April 30th, 2019. The reported EPS for the same quarter last year was $0.34. The estimated EPS forecast for the next fiscal year is $1.20 and is expected to report on September 25th, 2019.

To read the full Comtech Telecommunications Corp. (CMTL) report, download it here: https://Capital-Review.com/register/?so=CMTL

-----------------------------------------

ODONATE THERAPEUTICS, INC. (ODT) REPORT OVERVIEW

Odonate Therapeutics' Recent Financial Performance

Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.69. The estimated EPS forecast for the next fiscal year is -$4.51 and is expected to report on February 28th, 2020.

To read the full Odonate Therapeutics, Inc. (ODT) report, download it here: https://Capital-Review.com/register/?so=ODT

-----------------------------------------

ABOUT CAPITAL REVIEW

Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.

REGISTERED MEMBER STATUS

Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:

Morena Zambada, Media Department

Office: +1 (410) 280-7496

E-mail: media@Capital-Review.com

© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Related content
08 Aug - 
Yield Growth Corp Provides Mid-Year 2019 Corporate Upda..
01 Jul - 
Nevada Gold Mines Launched: Best Assets, Best People Wi..
28 May - 
Portola Pharmaceuticals to Participate in Two Upcoming ..
Del

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

#

EuroInvestor: In Focus
#

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
UPDATE - Yoko Ono and John Lennon Educational Tour Bus “Imagine A City With No Gun Violence!”
2
Translate Bio Announces Pricing of Public Offering of Common Stock
3
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Pluralsight, Inc. - PS
4
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SAExploration Holdings, Inc. - SAEX
5
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nektar Therapeutics - NKTR

Related stock quotes

Latest news


Copyright Berlingske Media 2019  Cookie- and Privacy policy  |  Cookies  |   General terms of trade  |   Terms of use and IP rights
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
18 September 2019 11:20:21
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20190829.2 - EUROWEB7 - 2019-09-18 12:20:21 - 2019-09-18 11:20:21 - 1000 - Website: OKAY